MARKET

APLMW

APLMW

APOLLOMICS INC
NASDAQ
0.0165
-0.0003
-1.79%
Closed 15:33 12/15 EST
OPEN
0.0145
PREV CLOSE
0.0168
HIGH
0.0165
LOW
0.0115
VOLUME
5.20K
TURNOVER
--
52 WEEK HIGH
0.0489
52 WEEK LOW
0.0047
MARKET CAP
--
P/E (TTM)
-0.0003
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APLMW last week (1208-1212)?
Weekly Report · 18h ago
APOLLOMICS: CO DOES NOT EXPECT TERMINATION TO HAVE MATERIAL ADVERSE EFFECT ON ITS OVERALL FINANCIAL CONDITION OR RESULTS OF OPERATIONS
Reuters · 3d ago
APOLLOMICS: TERMINATING AGREEMENT ON BASIS THAT EDISON FAILED TO FULFILL CERTAIN MATERIAL PERFORMANCE & REPORTING OBLIGATIONS
Reuters · 3d ago
Weekly Report: what happened at APLMW last week (1201-1205)?
Weekly Report · 12/08 09:11
Weekly Report: what happened at APLMW last week (1124-1128)?
Weekly Report · 12/01 09:10
Weekly Report: what happened at APLMW last week (1117-1121)?
Weekly Report · 11/24 09:11
APOLLOMICS ANNOUNCES SETTLEMENT OF CAYMAN LITIGATION
Reuters · 11/19 22:38
APOLLOMICS: UNDER AGREEMENT, RESOLVED AND CONCLUDED ALL MATTERS RELATED TO THE LEGAL PROCEEDINGS
Reuters · 11/19 21:07
More
About APLMW
Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.

Webull offers Apollomics Inc stock information, including NASDAQ: APLMW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLMW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLMW stock methods without spending real money on the virtual paper trading platform.